Loading company…
Resalis Therapeutics develops RNA-based therapies for metabolic conditions, including obesity and fatty liver disease.
Based in Turin, Italy, Resalis Therapeutics develops RES-010, an antisense oligonucleotide therapy targeting miR-22 for obesity and fatty liver disease. The candidate is intended to provide sustained weight loss and reduce hepatic steatosis, alone or with approved drugs. Founded in 2021, the company received venture funding from Sanofi in October 2024 to advance RES-010 toward a Phase 2 proof-of-concept trial.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in